Inhaled treprostinil in IPF: median FVC decline of 43.3 mL versus 196.2 mL on placebo
Over 52 weeks, participants on inhaled treprostinil lost a median 43.3 mL of absolute FVC versus 196.2 mL on placebo, a 130.1 mL treatment difference. The posted record gives sponsors and sites the full Phase 3 TETON-1 outcome set in idiopathic pulmonary fibrosis.
Machine-summarized from the primary sources listed below; not independently reported. How we use automation
Participants with idiopathic pulmonary fibrosis (IPF) who took inhaled treprostinil four times daily through an ultrasonic nebulizer had a median decline of 43.3 mL in absolute forced vital capacity (FVC) from baseline to Week 52, against a median decline of 196.2 mL on placebo, a treatment difference of 130.1 mL (95% confidence interval 82.2 to 178.1), the study record shows. Clinical worsening, defined as death, hospitalization due to a respiratory indication, or a 10% relative decline in % predicted FVC, occurred in 95 of 299 participants on the drug and 133 of 299 on placebo (hazard ratio 0.67, 95% confidence interval 0.52 to 0.88). United Therapeutics sponsored the 598-participant Phase 3 trial, and the study record now reports a result for the primary outcome and every secondary measure.
Why it matters
The trial, TETON-1, was designed to evaluate the superiority of inhaled treprostinil against placebo for the change in absolute FVC in subjects with idiopathic pulmonary fibrosis over a 52-week period, the record's study description states. It enrolled people already on the two background therapies the record names: at randomization 275 of 598 participants were taking nintedanib, 189 pirfenidone and 134 no background therapy. The study excluded anyone who had received PAH-approved therapy, including prostacyclin therapy such as treprostinil, within 60 days before baseline, and required an IPF diagnosis confirmed by central review of high-resolution computed tomography (HRCT). The record lists three publications on the program: a Phase 3 paper in N Engl J Med (2026 Jul 9), a combined analysis of the TETON-1 and TETON-2 trials in Am J Respir Crit Care Med (2026 Sep 23), and a plain language review of both studies in Expert Rev Respir Med (2026 Nov 2).
Primary and secondary outcomes
Results were first posted 2026-11-20, the study record shows. The study started 2021-04-21, completed its primary data collection 2026-02-02, and randomized 598 participants, 299 to each arm. The measures below are medians with 95% confidence intervals from the intention-to-treat population, which the record defines as all participants randomized who received at least one dose.
- Change in absolute FVC from baseline to Week 52 (primary outcome): -43.3 mL (95% confidence interval -92.1 to -9.1) on inhaled treprostinil versus -196.2 mL (95% confidence interval -227.1 to -155.6) on placebo; Hodges-Lehmann treatment difference 130.1 mL (95% confidence interval 82.2 to 178.1); p<0.0001
- Change in % predicted FVC: -1.4 (95% confidence interval -2.5 to -0.3) versus -5.4 (95% confidence interval -6.2 to -4.7) percentage of predicted; treatment difference 3.7 (95% confidence interval 2.4 to 5.0)
- Clinical worsening: 95 versus 133 participants; hazard ratio 0.67 (95% confidence interval 0.52 to 0.88); p=0.0034
- First acute exacerbation of IPF: 10 versus 19 participants; hazard ratio 0.50 (95% confidence interval 0.23 to 1.08)
- Overall survival at Week 52: 22 versus 32 deaths; hazard ratio 0.50 (95% confidence interval 0.38 to 1.13)
- Change in K-BILD total score: -1.1 (95% confidence interval -2.1 to 0.0) versus -2.4 (95% confidence interval -3.8 to -1.2); treatment difference 1.40 (95% confidence interval -0.15 to 2.94); p=0.0760
Trial design and participants
Participants self-administered treprostinil for inhalation solution (0.6 mg/mL) by ultrasonic nebulizer, a dose of approximately 6 mcg per breath, starting at 3 breaths four times daily and titrated to a target of 12 breaths four times daily or the maximum clinically tolerated dose. All were at least 40 years of age with FVC at least 45% predicted at screening. Participants were 52 to 91 years old, with 462 men and 136 women; time since IPF diagnosis ranged from 0.08 to 21.39 years. At baseline the group had a median FVC of 2636.0 mL, 72.60% predicted FVC, 47.90% predicted DLCO, and 117 of 598 participants used supplemental oxygen. Study sites sat in the United States and Canada; 218 participants on the drug and 216 on placebo completed the overall study, with withdrawal by subject ending 38 and 31, adverse events 19 and 22, death 8 and 14, and lung transplantation 6 and 6.
Safety measures
Serious adverse events were reported for 54 of 299 participants on inhaled treprostinil and 72 of 299 on placebo, other adverse events for 287 and 280, and deaths for 22 and 34; the record notes deaths here were captured through 30 days after the Week 52 visit, so the count differs from the Week 52 survival outcome. Cough affected 164 participants on the drug versus 99 on placebo, headache 91 versus 48, and throat irritation 42 versus 16.
What comes next
The record states that participants who complete the Week 52 visit can be offered entry into an open-label extension study after the final study visit.